Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) insider Lisa Bright sold 155 shares of the business’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $163.20, for a total transaction of $25,296.00. Following the completion of the sale, the insider now directly owns 18,305 shares in the company, valued at approximately $2,987,376. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Lisa Bright also recently made the following trade(s):
- On Thursday, August 25th, Lisa Bright sold 246 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00.
Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 152.74 on Monday. The firm’s 50-day moving average is $157.61 and its 200-day moving average is $150.68. The firm’s market capitalization is $3.78 billion. Intercept Pharmaceuticals Inc. has a 52 week low of $89.76 and a 52 week high of $217.99.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the consensus estimate of ($3.69) by $0.55. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The business had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. During the same period last year, the business earned ($1.99) EPS. The business’s revenue was up 1140.4% on a year-over-year basis. Equities analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current year.
A number of analysts have recently commented on ICPT shares. Robert W. Baird reissued an “outperform” rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 15th. Wedbush reissued an “outperform” rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, June 24th. Cantor Fitzgerald started coverage on shares of Intercept Pharmaceuticals in a research report on Wednesday, July 6th. They issued a “sell” rating and a $58.00 price objective on the stock. Laidlaw lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and cut their price objective for the stock from $345.00 to $105.00 in a research report on Friday, August 5th. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $200.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Five equities research analysts have rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the company. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $177.67.
Institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA boosted its position in shares of Intercept Pharmaceuticals by 6.5% in the third quarter. BNP Paribas Arbitrage SA now owns 4,368 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 267 shares during the period. Macquarie Group Ltd. boosted its stake in Intercept Pharmaceuticals by 129.1% in the second quarter. Macquarie Group Ltd. now owns 22,690 shares of the biopharmaceutical company’s stock worth $3,237,000 after buying an additional 12,788 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in Intercept Pharmaceuticals during the second quarter worth approximately $384,000. Schwab Charles Investment Management Inc. boosted its stake in Intercept Pharmaceuticals by 19.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 56,429 shares of the biopharmaceutical company’s stock worth $8,052,000 after buying an additional 9,112 shares during the last quarter. Finally, Amalgamated Bank boosted its stake in Intercept Pharmaceuticals by 39.0% in the second quarter. Amalgamated Bank now owns 2,619 shares of the biopharmaceutical company’s stock worth $413,000 after buying an additional 735 shares during the last quarter. Institutional investors and hedge funds own 81.86% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.